McMaster chemists develop foolproof new test to track the fats we eat

A team of researchers at McMaster has developed a reliable and accurate blood test to track individual fat intake, a tool that could guide public health policy on healthy eating.

By Michelle Donovan May 15, 2020

Phil Britz-McKibbin is one of a team of Mac researchers who have developed a blood test to track individual fat intake.

Experts Featured In This Story

Sonia Anand
Sonia Anand

Professor

See Profile
Philip Britz Mckibbin
Philip Britz Mckibbin

Professor

See Profile
Stuart Phillips
Stuart Phillips

Professor

See Profile

A team of researchers at McMaster has developed a reliable and accurate blood test to track individual fat intake, a tool that could guide public health policy on healthy eating.

Establishing reliable guidelines has been a significant challenge for nutritional epidemiologists until now, because they have to rely on study participants faithfully recording their own consumption, creating results that are prone to human error and selective reporting, particularly when in the case of high-fat diets.

For the study, published in the Journal of Lipid Research, chemists developed a test, which detects specific non-esterified fatty acids (NEFAs), a type of circulating free fatty acid that can be measured using a small volume of blood sample.

“Epidemiologists need better ways to reliably assess dietary intake when developing nutritional recommendations,” says Philip Britz-McKibbin, professor in the Department of Chemistry & Chemical Biology at McMaster and lead author of the study

“The food we consume is highly complex and difficult to measure when relying on self-reporting or memory recall, particularly in the case of dietary fats. There are thousands of chemicals that we are exposed to in foods, both processed and natural,” he says.

The study was a combination of two research projects Britz-McKibbin conducted with Sonia Anand in the Department of Medicine and Stuart Phillips in the Department of Kinesiology.

Researchers first assessed the habitual diet of pregnant women in their second trimester, an important development stage for the fetus. The women, some of whom were taking omega-3 fish oil supplements, were asked to report on their average consumption of oily fish and full-fat dairy and were then tested with the new technology. Their study also monitored changes in omega-3 NEFAs in women following high-dose omega-3 fish oil supplementation as compared to a placebo.

Researchers were able to prove that certain blood NEFAs closely matched the diets and/or supplements the women had reported, suggesting the dietary biomarkers may serve as an objective tool for assessment of fat intake.

“Fat intake is among the most controversial aspects of nutritional public health policies given previously flawed low-fat diet recommendations, and the growing popularity of low-carb/high-fat ketogenic based diets,” says Britz-McKibbin.

“If we can measure it reliably, we can begin to study such questions as: Should pregnant women take fish oil? Are women deficient in certain dietary fats? Does a certain diet or supplement lead to better health outcomes for their babies?”

Researchers plan to study what impact NEFAs and other metabolites associated with dietary exposures during pregnancy, might have on childhood health outcomes in relation to the obesity, metabolic syndrome and chronic disease risk later in life.

The study was funded by the NSERC and Genome Canada.

A close-up of a vial containing a clear peptide blend of BPC-157 and TB-500, next to two single-use syringes.

What do we know about ‘research only’ peptides? Q&A with expert Stuart Phillips 

Unapproved peptides that lack safety and efficacy data carry substantial risks and belong in a laboratory, not your body, Phillips warns.
Scientist Jon Stokes stands in a university corridor, wearing a hoodie and ball cap.

McMaster researcher awarded more than $2M from Weston Family Foundation to advance precision antibiotic for IBD

The funding will accelerate the move toward human trials, enabling preclinical studies, regulatory preparation and early-phase clinical trial design.
?A stent being held by a clinician wearing gloves.

Minimally invasive procedure offers new hope for patients with complications from blood clots

Patients who had the procedure experienced a significantly better quality of life and less severe post-thrombotic syndrome, a painful condition that affects 20 to 50 per cent of people who had a deep vein thrombosis.